基于加权TOPSIS法的美罗培南药物利用评价  

Evaluation on meropenem using based on weighted TOPSIS method

作　　者：邢蓉[1] 朱裕林[1] 宋佳伟[1] 颜青[2] 刘雁[1] 张乃菊[1] 王慕华[1] 苏文燕[3] 

机构地区：[1]蚌埠医学院第一附属医院,安徽蚌埠233004 [2]卫生部医院管理研究所,北京100191 [3]蚌埠医学院药学系2008级,安徽蚌埠233000

出　　处：《中国新药与临床杂志》2013年第5期389-393,共5页Chinese Journal of New Drugs and Clinical Remedies

基　　金：卫生部WHO(2010-2011)双年度项目(WPCHN1004601);蚌埠市科技局项目(20100322)

摘　　要：目的建立美罗培南药物利用评价方法，为合理应用美罗培南提供依据。方法参考美罗培南应用指南，建立美罗培南药物合理利用评价细则：采用加权TOPSIS法对我院2011～2012年147例应用美罗培南的病例进行评价。结果147个病例中相对接近度大于90％的有14例（占9．5％）。相对接近度介于80％～90％间有9例（占6．1％），相对接近度介于70％～80％间有24例（占16．3％），相对接近度介于60％一70％间有41例（占27．9％），相对接近度小于60％有59例（占40．1％）。结论采用加权TOPSIS法作为美罗培南药物利用评价方法是合理可行的。我院美罗培南的不合理用药现象较为明显．应规范用药以减少不合理用药现象。AIM To establish a drug using evaluation method of meropenem and provide a basis for the reasonable use of meropenem. METHODS Reasonable use evaluation system of meropenem was established with reference to the application guide of meropenem, and weighted TOPSIS was used to evaluate 147 patients taken with meropenem during 2011--2012 in our hospital. RESULTS Among the 147 patients, there were 14 cases whose relative approach degree were lager than 90% （account for 9.5% ） , 9 cases whose relative approach degree were between 80% and 90% （account for 6.1%）, 24 cases whose relative approach degree were between 70% and 80% （account for 16.3%）, 41 cases whose relative approach degree were between 60% and 70% （account for 27.9%）, and 59 cases whose relative approach degree were below 60% （account for 40.1%）. CONCLUSION It is reasonable and feasible to adopt weighted TOPSIS as the drug using evaluation method ofmeropenem. Unreasonable use of meropenem exists obviously in our hospital, so drug use should be standardized to reduce the unreasonable phenomenon.

关 键 词：加权TOPSIS法 美罗培南 药物利用评价 

分 类 号：R978.1[医药卫生—药品]